Navigation Links
Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Date:5/27/2009

comes but also allow more patients to receive timely treatments.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem (iPS) cell technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. In addition, Fate Therapeutics and Stemgent have formed an alliance - Catalyst - a collaborative program to provide its partners with first access to the most advanced induced pluripotent stem (iPS) cell technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender ... (NASDAQ: VPHM).   As a result of the ... and Shire expects to complete the tender offer on January ... the satisfaction of all of the remaining conditions to the ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nasdaq: NVGN ), announced today that following ... held on 7 May, 2012, its Board of Directors ... Marshall Edwards, Inc. ("MEI") under the MEI rights offering ... rights that have not been otherwise exercised by MEI ...
... 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ), ... novel therapeutics targeting cancer metabolism, announced that its majority ... million of Units, subject to availability, in Marshall Edwards, ... Novogen stockholders in Sydney on Monday. Pursuant ...
Cached Medicine Technology:Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Voters in New Television Ad, SACRAMENTO, Calif., Oct. ... a new television spot featuring Senator Diane Feinstein,who, speaking ... terrible mistake for California. It,s about discrimination and we ... moved to have the strong, trusted and independent voice ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... BIRMINGHAM, Ala. and NASHVILLE, Tenn., Oct. 28 /PRNewswire-FirstCall/,-- ... that the PICA Group,will become part of ProAssurance ... Group (PICA) is the nation,s leading provider of ... 9,800,podiatric physicians in 47 states and the District ...
... 28 Align,Technology, Inc. (Nasdaq: ALGN ) today reported ... 30, 2008., Total net revenues for the third quarter ... million reported in the third quarter of,2007 (Q3 07) and ... (Q2 08)., On a generally accepted accounting principles (GAAP) ...
... Oct. 28 Blue Mountain Quality,Resources, Inc. ... Mountain Regulatory Asset Manager(R) to satisfy their ... of their enterprise-wide,SAP(R) implementation., "Alexion is ... productivity in,its manufacturing facilities and other operations," ...
... New Findings Suggest Soy Isoflavones Contribute to Blood Vessels, Healthy ... ... study examines how a certain,naturally-occurring component of soy may enhance the function ... to,the Center for Disease Control and Prevention, heart disease is the,nation,s number ...
Cached Medicine News:Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:The PICA Group Will Become Part of ProAssurance 2Health News:The PICA Group Will Become Part of ProAssurance 3Health News:The PICA Group Will Become Part of ProAssurance 4Health News:The PICA Group Will Become Part of ProAssurance 5Health News:The PICA Group Will Become Part of ProAssurance 6Health News:The PICA Group Will Become Part of ProAssurance 7Health News:The PICA Group Will Become Part of ProAssurance 8Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 13Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 14Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:Study Shows How Soy Compound Lowers Blood Pressure and Stroke Risk 2
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: